HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CQA 206-291

Also Known As:

CQA-206-291; N,N-diethyl-N-(1-ethyl-6-methylergoline-8-yl)sulfamide

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Ergot Alkaloids: 208
    - Ergolines: 109
      - CQA 206-291: 5
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Ergolines: 109
      - CQA 206-291: 5

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 11/01/1990 - "CQA 206-291 in Parkinson's disease: an acute single escalating dosage study." 04/01/1991 - "CQA 206-291 in Parkinson's disease." 11/01/1990 - "CQA 206-291, a new ergot derivative with a "biphasic" dopaminergic profile, was studied in 6 patients with longstanding Parkinson's disease suffering from pronounced fluctuations in hourly mobility. " 04/01/1991 - "CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. " 08/01/1990 - "CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease."
2.	Pleural Effusion (Pleural Effusions) 04/01/1995 - "We describe a parkinsonian patient who developed a slight asymptomatic pleural effusion during prolonged therapy with low dose bromocriptine (BCR) in addition to levodopa, following prior treatment with CQA 206-291. "

Related Drugs and Biologics

1.	Dopamine Antagonists
2.	Dopamine Agonists (Dopamine Agonist)
3.	Levodopa (L Dopa)
4.	Bromocriptine (Parlodel)

Related Therapies and Procedures

1.	Therapeutics